<DOC>
	<DOC>NCT01526980</DOC>
	<brief_summary>This trial is conducted in Europe. The aim of this trial is to compare the glycaemic control of biphasic insulin aspart 70 + biphasic insulin aspart 30 with biphasic human insulin 30 in subjects with type 2 diabetes.</brief_summary>
	<brief_title>Glycaemic Control of Biphasic Insulin Aspart 70 and 30 in Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart, insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin, Long-Acting</mesh_term>
	<mesh_term>Insulin, Isophane</mesh_term>
	<criteria>Subjects with Type 2 diabetes Treatment with BHI (biphasic human insulin) 30 twice daily for at least three months HbA1c maximum 10.0% BMI (Body Mass Index) maximum 35.0 kg/m2 Able and willing to perform selfblood glucose monitoring (SBGM) The receipt of any investigational drug within the last 30 days prior to this trial Total daily insulin dose minimum 2.0 U/(kgÂ·day) A history of drug abuse or alcohol dependence within the last 5 years Impaired hepatic function Impaired renal function Cardiac disease Severe, uncontrolled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>